Holen Sie sich die Stockscreener-App
117.77
0.94%
1.10
Handel nachbörslich:
117.77
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Published on: 2025-08-16 00:17:35 - thegnnews.com
BofA Securities raises Jazz Pharmaceuticals stock price target on Modeyso potential - Investing.com UK
United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 20337.88% CAGR Driven by Novel Therapies and Better Diagnosis - Yahoo Finance
JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook - Yahoo Finance
Is FDA’s First-Ever Approval of Modeyso Shaping the Investment Case for Jazz Pharmaceuticals (JAZZ)? - simplywall.st
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Using flow based indicators on Jazz Pharmaceuticals plcTechnical Analysis of Growth Stock Opportunities - Newser
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance
FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times
How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser
Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com
Jazz Pharmaceuticals stock surges 4.8% on FDA approval for Modeyso treatment - AInvest
Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today - Yahoo Finance
Jazz Pharmaceuticals Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript - Insider Monkey
FDA approval of Modeyso for glioma - The Pharma Letter
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - MSN
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy - Pharmaceutical Technology
Morgan Stanley Lowers Jazz Pharmaceuticals Price Target to $162, Maintains Overweight Rating - AInvest
Beyond the Balance Sheet: What SWOT Reveals About Jazz Pharmaceu - GuruFocus
Jazz Earnings: Xywav and Epidiolex Drive Growth; US Approval for Chimerix's Dordaviprone Promising - Morningstar
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech
US FDA approves Jazz Pharma's drug for rare brain tumor - Reuters
Rising Star: Quinn Emanuel's Frank Calvosa - Law360
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma - Yahoo Finance
Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView
What data driven models say about Jazz Pharmaceuticals plc’s futureFree Triple Digit Return Stock Predictions - Newser
Jazz Pharmaceuticals plc 2025 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... By GuruFocus - Investing.com Canada
Jazz: Q2 Earnings Snapshot - Greenwich Time
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... - Yahoo Finance
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should KnowTechnical Analysis of Growth Stock Opportunities - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitFree Wealth Building Stock Market Ideas - Newser
Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition - TipRanks
Jazz Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Jazz Pharmaceuticals Sticks To Its Game Plan Despite Setbacks - Finimize
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Jazz Pharmaceuticals plc, Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Jazz Pharmaceuticals misses on Q2 earnings, shares fall By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals misses on Q2 earnings, shares fall - Investing.com
Jazz Pharma earnings missed by $0.63, revenue topped estimates - Investing.com South Africa
Jazz Pharmaceuticals Q2 revenue up 2% - MarketScreener
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted Loss $8.25 per Share, vs. FactSet Est Loss of $7.61 - MarketScreener
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):